Skip to main content
SpringerLink
Log in

The Optimal Management of Hairy Cell Leukaemia

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

Hairy cell leukaemia is an uncommon B cell chronic lymphoproliferative disorder characterised by circulating lymphocytes displaying prominent cytoplasmic projections. Therapy is initiated for severe cytopenias or recurrent infections. Splenectomy, the first standard treatment, is now less commonly used as primary treatment. Interferon-α (IFNα) induces partial responses in most patients but complete responses in only a few. Adverse effects from IFNα are common but not life-threatening. The ability of two newer purine analogues, pentostatin (2′-deoxycoformycin) and cladribine (2-chlorodeoxyadenosine), to induce long-lasting complete remissions in the majority of patients has revolutionised the treatment of this disease. Cladribine is emerging as the treatment of choice because of its favourable toxicity profile, brief duration of treatment, high percentage of unmaintained complete remissions and low incidence of relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review of 71 cases. Ann Intern Med 1978; 89: 677–83.

    PubMed  CAS  Google Scholar 

  2. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958; 13: 609–30.

    PubMed  CAS  Google Scholar 

  3. Schrek R, Donnelly WJ. ‘Hairy’ cells in blood in lymphoreticular neoplastic disease and ‘flagellated’ cells of normal lymph nodes. Blood 1966; 27: 199–211.

    PubMed  CAS  Google Scholar 

  4. Visser L, Shaw A, Slupsky J, et al. Monoclonal antibodies reactive with hairy cell leukemia. Blood 1989; 74: 320–5.

    PubMed  CAS  Google Scholar 

  5. Richards JM, Mick R, Latta JM, et al. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 1990; 76: 1941–5.

    PubMed  CAS  Google Scholar 

  6. Saven A, Piro LD. Treatment of hairy cell leukemia. Blood 1992; 79: 1111–20.

    PubMed  CAS  Google Scholar 

  7. Bouroncle BA. Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 1979; 53: 412–36.

    PubMed  CAS  Google Scholar 

  8. Mintz U, Golomb HM. Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res 1979; 39: 2366–70.

    PubMed  CAS  Google Scholar 

  9. Golomb HM, Vardiman JW. Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 1983; 61: 349–52.

    PubMed  CAS  Google Scholar 

  10. Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer 1981; 47: 2066–76.

    Article  PubMed  CAS  Google Scholar 

  11. Ratain MJ, Vardiman JW, Barker CM, et al. Prognostic variables in hairy cell leukemia after splenectomy as initial therapy. Cancer 1988; 62: 2420–4.

    Article  PubMed  CAS  Google Scholar 

  12. Golde DW. Therapy of hairy-cell leukemia. N Engl J Med 1982; 307: 495–6.

    Article  PubMed  CAS  Google Scholar 

  13. Lembersky BC, Ratain MJ, Golomb HM. Skeletal complications in hairy cell leukemia: diagnosis and therapy. J Clin Oncol 1988; 6: 1280–4.

    PubMed  CAS  Google Scholar 

  14. Quesada JR, Reuben J, Manning JT, et al. Alpha-interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984; 310: 15–8.

    Article  PubMed  CAS  Google Scholar 

  15. Quesada JR, Gutterman J, Hersh EM. Treatment of hairy cell leukemia with alpha interferons. Cancer 1986; 57: 1678–80.

    Article  PubMed  CAS  Google Scholar 

  16. Quesada JR, Hersh EM, Manning J, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986; 68: 493–7.

    PubMed  CAS  Google Scholar 

  17. Golomb HM, Jacobs A, Fefer A, et al. Alpha-2 interferon therapy of hairy cell leukemia: a multicenter study of 64 patients. J Clin Oncol 1986; 4: 900–5.

    PubMed  CAS  Google Scholar 

  18. Golomb HM, Fefer A, Golde DW, et al. Sequential evaluation of alpha-2b interferon treatment in 128 patients with hairy cell leukemia. Semin Oncol 1987; 14 Suppl. 2: 13–7.

    PubMed  CAS  Google Scholar 

  19. Golomb HM, Fefer A, Golde DW, et al. Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon alfa-2b. Semin Oncol 1988; 15 Suppl. 5: 7–9.

    PubMed  CAS  Google Scholar 

  20. Golomb H, Fefer A, Golde D, et al. Update of a multi-institutional study of 195 patients (pts) with hairy cell leukemia (HCL) treated with interferon alfa-2b (IFN) [abstract]. Proc Am Soc Clin Onc 1990; 9: 831.

    Google Scholar 

  21. Golomb HM, Ratain MJ, Fefer A, et al. Randomized study of the duration of treatment with interferon alfa-2b in patients with hairy cell leukemia. J Natl Cancer Inst 1988; 80: 369–73.

    Article  PubMed  CAS  Google Scholar 

  22. Glaspy JA, Marcus SG, Ambersley J, et al. Recombinant beta-serine-interferon in hairy cell leukemia compared prospectively with results with recombinant alpha-interferon. Cancer 1989; 64: 409–13.

    Article  PubMed  CAS  Google Scholar 

  23. Dutcher JP, Salva KM, Wiernik P. Successful treatment of hairy cell leukemia with 2′-deoxycoformycin after failure of interferon alpha or beta. Am J Clin Oncol 1990; 13: 290–3.

    Article  PubMed  CAS  Google Scholar 

  24. Quesada JR, Alexanian R, Kurzrock R, et al. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom’s macroglobulinemia. Am J Hematol 1988; 29: 1–4.

    Article  PubMed  CAS  Google Scholar 

  25. Taylor-Papadimitriou J. Effects of interferons on cell growth and function. In: Gresser I, editor. Interferon 1980. Vol. 2. New York: Academic Press, 1980: 13–46.

    Google Scholar 

  26. Foon KA, Maluish AE, Abrams PG, et al. Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results. Am J Med 1986; 80: 351–6.

    Article  PubMed  CAS  Google Scholar 

  27. Ruco LP, Procapio A, Maccallini V, et al. Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 1983; 61: 1132.

    PubMed  CAS  Google Scholar 

  28. Lee SH, Kelley S, Chin H, et al. Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes. Cancer Res 1982; 42: 1312.

    PubMed  CAS  Google Scholar 

  29. Genot E, Bismuth G, Degos L, et al. Interferon-α down-regulates the abnormal intracytoplasmic free calcium concentration of tumor cells in hairy cell leukemia. Blood 1992; 80: 2060–5.

    PubMed  CAS  Google Scholar 

  30. Moormeier JA, Ratain MJ, Westbrook CA, et al. Low-dose interferon alpha-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst 1989; 81: 1172–4.

    Article  PubMed  CAS  Google Scholar 

  31. Jaiyesimi IA, Kantarjian HM, Estey EH. Advances in therapy for hairy cell leukemia: a review. Cancer 1993; 72: 5–14.

    Article  PubMed  CAS  Google Scholar 

  32. Jacobs AD, Champlin RE, Golde DW. Recombinant alpha-2 interferon for hairy cell leukemia. J Clin Oncol 1985; 65: 1017–20.

    CAS  Google Scholar 

  33. Ratain MJ, Golomb HM, Vardiman JW, et al. Interferon alpha-2b therapy for hairy cell leukemia in 69 patients: a 6-year update [abstract]. Blood 1989; 74: 76.

    Google Scholar 

  34. Lauria F, Benfenati D, Zinzani PL, et al. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia patients relapsed after α-interferon [abstract]. Blood 1991; 78 Suppl. 1: 34a.

    Google Scholar 

  35. Kampmeier P, Spielberger R, Dickstein J, et al. Increased incidence of second neoplasms in patients treated with interferon α-2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994; 83: 2931–8.

    PubMed  CAS  Google Scholar 

  36. Von Wussow P, Pralle H, Hochkeppel H, et al. Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukemia. Blood 1991; 78: 38–43.

    Google Scholar 

  37. Lill MCC, Golde DW. Treatment of hairy-cell leukemia. Blood Rev 1990; 4: 238–44.

    Article  PubMed  CAS  Google Scholar 

  38. Carrera CJ, Piro LD, Miller WE, et al. Remission induction in hairy cell leukemia by treatment with 2-chlorodeoxyadenosine: role of DNA strand breaks and NAD depletion [abstract]. Clin Res 1987; 35: 597A.

    Google Scholar 

  39. Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronoc lymphocytic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-B-D-arabinosyl-2-fluorodenine. Blood 1993; 81: 143–50.

    PubMed  CAS  Google Scholar 

  40. Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 1985; 75: 377–83.

    Article  PubMed  CAS  Google Scholar 

  41. o’Dwyer PJ, Cheson BD, Leyland-Jones B, et al. Deoxycoformycin: an active new drug for indolent lymphomas and hairy cell leukemia. Oncology 1988; 2: 17–22.

    PubMed  Google Scholar 

  42. Spiers ASD, Parekh SJ. Pentostatin (2′-deoxycoformycin, DCF) is active in hairy cell leukemia (HCL) [abstract]. Blood 1983; 62: 208.

    Google Scholar 

  43. Spiers ASD, Moore D, Cassileth PA, et al. Remissions in hairy cell leukemia with pentostatin (2′deoxycoformycin). N Engl J Med 1987; 316: 825–30.

    Article  PubMed  CAS  Google Scholar 

  44. Spiers ASD, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 1984; 2: 1336–42.

    PubMed  CAS  Google Scholar 

  45. Kraut ED, Bouroncle BA, Grever MR. Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 1986; 68: 1119–22.

    PubMed  CAS  Google Scholar 

  46. Spiers ASD, Parekh SJ. Complete remission in hairy cell leukemia achieved with pentostatin. Lancet 1984; 1: 1080–1.

    Article  PubMed  CAS  Google Scholar 

  47. Cassileth PA, Cheuvant B, Spiers ASD, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9: 243–6.

    PubMed  CAS  Google Scholar 

  48. Ho AD, Thaler J, Mandelli F, et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. J Clin Oncol 1989; 7: 1533–8.

    PubMed  CAS  Google Scholar 

  49. Sorensen JM, Chun HG, Vena D, et al. Pentostatin (DCF) therapy for hairy cell leukemia (HCL): update of a Group C protocol of 208 patients (pts) who have failed interferon-alpha (IFNa) [abstract]. Proc Am Soc Clin Oncol 1991; 10: 232.

    Google Scholar 

  50. Grever M, Kopecky K, Head D, et al. A randomized comparison of deoxycoformycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): an NCI-sponsored Intergroup Study (SWOG, ECOG, CALGB, NCIC, CTG) [abstract]. Proc Am Soc Clin Oncol 1992; 11: 868.

    Google Scholar 

  51. Johnston JB, Glazer RI, Pugh L, et al. The treatment of hairycell leukemia with 2′-deoxycoformycin. Br J Haematol 1986; 63: 525–34.

    Article  PubMed  CAS  Google Scholar 

  52. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7: 168–72.

    PubMed  CAS  Google Scholar 

  53. Foon KA, Nakano GM, Koller CA, et al. Response to 2′-deoxycoformycin after failure of interferon-α in nonsplenectomized patients with hairy cell leukemia. Blood 1986; 68: 297–300.

    PubMed  CAS  Google Scholar 

  54. Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8: 848–55.

    PubMed  CAS  Google Scholar 

  55. Urba WJ, Baseler MW, Kopp WC, et al. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989; 73: 38–46.

    PubMed  CAS  Google Scholar 

  56. Seto S, Carrera CJ, Wasson DB, et al. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J Immunol 1986; 136: 2839–43.

    PubMed  CAS  Google Scholar 

  57. Carrera CJ, Terai C, Piro L, et al. 2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. J Purine Pyrimidine Res 1991; 2 Suppl. 1: 15–38.

    Google Scholar 

  58. Piro LD, Miller WE, Carrera CJ, et al. Hairy-cell leukemia [letter]. N Engl J Med 1987; 317: 901.

    Article  Google Scholar 

  59. Piro LD, Saven A, Ellison D, et al. Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL) [abstract]. Proc Am Soc Clin Oncol 1992; 11: 259.

    Google Scholar 

  60. Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann Intern Med 1993; 119: 278–83.

    PubMed  CAS  Google Scholar 

  61. Hakimian D, Tallman MS, Kiley C, et al. Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1993; 82: 1798–802.

    PubMed  CAS  Google Scholar 

  62. Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994; 84: 4310–5.

    PubMed  CAS  Google Scholar 

  63. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chloro-deoxyadenosine (2-CdA) does not eradicate leukemic cells in hairy cell leukemia (HCL) patients achieving complete remission [abstract]. Blood 1993; 82 Suppl.: 142a.

    Google Scholar 

  64. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117–21.

    Article  PubMed  CAS  Google Scholar 

  65. Piro LD, Ellison D, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994; 14 Suppl. 1: 121–5.

    Article  PubMed  Google Scholar 

  66. Carrera CJ, Piro LD, Saven A, et al. Restoration of lymphocyte subsets following 2-chlorodeoxyadenosine remission induction in hairy cell leukemia [abstract]. Blood 1990; 76 Suppl. 1: 260a.

    Google Scholar 

  67. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672–81.

    PubMed  CAS  Google Scholar 

  68. Seymour J, Kurzrock R, Freireich EJ, et al. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906–11.

    PubMed  CAS  Google Scholar 

  69. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25.

    PubMed  CAS  Google Scholar 

  70. Keating MJ, Kantarjian H, o’Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44–9.

    PubMed  CAS  Google Scholar 

  71. Keating MJ, o’Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–84.

    PubMed  CAS  Google Scholar 

  72. Kraut E, Chun H. Fludarabine phosphate in refractory hairy cell leukemia. Am J Hematol 1991; 37: 59–60.

    Article  PubMed  CAS  Google Scholar 

  73. Kantarjian HM, Redman J, Keating MJ. Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 1990; 17 Suppl. 8: 66–70.

    PubMed  CAS  Google Scholar 

  74. Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer 1991; 67: 1291–3.

    Article  PubMed  CAS  Google Scholar 

  75. Glaspy JA, Baldwin GC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988; 109: 789–95.

    PubMed  CAS  Google Scholar 

  76. Seymour JF, Estey EH, Keating MJ, et al. Interferon-α is effective in patients with hairy cell leukemia relapsing after 2-chlorodeoxyadenosine [abstract]. Proc Am Soc Clin Oncol 1994; 13: 1033.

    Google Scholar 

  77. Rai K, Mick R, Ozer H, et al. Alpha-interferon therapy in untreated active hairy cell leukemia: a Cancer and Leukemia Group B (CALGB) study [abstract]. Proc Am Soc Clin Oncol 1987; 6: 159.

    Google Scholar 

  78. Grem J, King S, Cheson B, et al. Pentostatin in hairy cell leukemia: treatment by the special exception mechanism. J Natl Cancer Inst 1989; 81: 448–53.

    Article  PubMed  CAS  Google Scholar 

  79. Estey EM, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992; 79: 882–7.

    PubMed  CAS  Google Scholar 

  80. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79: 888–94.

    PubMed  CAS  Google Scholar 

  81. Hoffman M, Rai K, Sawitsky A, et al. 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia [abstract]. Blood 1991; 78 Suppl. 1: 454a.

    Google Scholar 

  82. Tallman MS, Hakimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 9: 2203–9..

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, MS312, Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, California, CA 92037, USA

    Russell Gollard, Thomas C. Lee, Lawrence D. Piro &  Alan Saven

Authors
  1. Russell Gollard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas C. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence D. Piro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alan Saven
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gollard, R., Lee, T.C., Piro, L.D. et al. The Optimal Management of Hairy Cell Leukaemia. Drugs 49, 921–931 (1995). https://doi.org/10.2165/00003495-199549060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199549060-00006

Keywords

Search

Navigation